Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Vyne Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
VYNE
Nasdaq
8731
https://vynetherapeutics.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Vyne Therapeutics Inc
VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
- Mar 19th, 2024 12:00 pm
VYNE Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
- Mar 3rd, 2024 12:03 pm
VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update
- Feb 29th, 2024 1:00 pm
VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium
- Feb 27th, 2024 1:00 pm
VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
- Feb 21st, 2024 1:00 pm
Favourable Signals For VYNE Therapeutics: Numerous Insiders Acquired Stock
- Feb 2nd, 2024 10:50 am
VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo
- Jan 10th, 2024 1:00 pm
VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors
- Jan 3rd, 2024 1:00 pm
VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
- Nov 13th, 2023 12:45 pm
VYNE Therapeutics to Host Virtual R&D Day Event on November 9, 2023
- Nov 7th, 2023 1:00 pm
VYNE Therapeutics Announces Closing of Previously Announced Private Placement of $88.2 Million
- Nov 1st, 2023 8:15 pm
VYNE Therapeutics Reports Positive Results from Preclinical Models for Oral BD2-Selective BET Inhibitor VYN202
- Oct 30th, 2023 11:20 am
VYNE Therapeutics Announces Private Placement of $88 Million
- Oct 30th, 2023 11:05 am
VYNE Therapeutics Announces Positive Data from Phase 1b Trial for Novel BET Inhibitor VYN201 in Patients with Nonsegmental Vitiligo
- Oct 30th, 2023 11:00 am
VYNE Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
- Sep 6th, 2023 12:00 pm
VYNE Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
- Aug 14th, 2023 12:00 pm
VYNE Therapeutics to Attend BIO International Convention
- May 18th, 2023 12:00 pm
VYNE Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
- May 11th, 2023 8:01 pm
VYNE Therapeutics Announces Selection of Development Candidate VYN202, a Potential Best-in-Class Oral Small Molecule BD2-Selective BET Inhibitor for the Treatment of Immuno-Inflammatory Conditions
- May 1st, 2023 12:00 pm
VYNE Therapeutics Announces Positive Preclinical Data for Inhaled Formulation of VYN201 in an In Vivo Model of Idiopathic Pulmonary Fibrosis
- Apr 19th, 2023 12:00 pm
Scroll